Back

Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for Addiction

Nikolova, Y. S.; Ruocco, A. C.; Felsky, D.; Lange, S.; Prevot, T. D.; Vieira, E.; Voineskos, D.; Wardell, J. D.; Blumberger, D. M.; Clifford, K.; Dharavath, R. N.; Gerretsen, P.; Hassan, A. N.; Jennings, S. K.; LeFoll, B.; Melamed, O.; Orson, J.; Pangarov, P.; Quigley, L. ,; Russell, C.; Shield, K.; Sloan, M. E.; Smoke, A.; Tang, V.; Cabrera, D. V.; Wang, W.; Wells, S.; Wickramatunga, R.; Sibille, E. M.; Quilty, L. C.; CDiA Program Study Group,

2024-08-31 addiction medicine
10.1101/2024.08.30.24312806 medRxiv
Show abstract

BackgroundSubstance use disorders (SUDs) are pressing global public health problems. Executive functions (EFs) are prominently featured in mechanistic models of addiction. However, there remain significant gaps in our understanding of EFs in SUDs, including the dimensional relationships of EFs to underlying neural circuits, molecular biomarkers, disorder heterogeneity, and functional ability. To improve health outcomes for people with SUDs, interdisciplinary clinical, preclinical and health services research is needed to inform policies and interventions aligned with biopsychosocial models of addiction. Here, we introduce Cognitive Dysfunction in the Addictions (CDiA), an integrative team-science and translational research program, which aims to fill these knowledge gaps and facilitate research discoveries to enhance treatments for people living with SUDs. MethodsThe CDiA Program comprises seven complementary interdisciplinary projects that aim to progress understanding of EF in SUDs and investigate new biological treatment approaches. The projects draw on a diverse sample of adults aged 18-60 (target N=400) seeking treatment for addiction, who are followed prospectively over one year to identify EF domains crucial to recovery. Projects 1-3 investigate SUD symptoms, brain circuits, and blood biomarkers and their associations with both EF domains (inhibition, working memory, and set-shifting) and functional outcomes (disability, quality of life). Projects 4 and 5 evaluate interventions for addiction and their impacts on EF: a clinical trial of repetitive transcranial magnetic stimulation and a preclinical study of potential new pharmacological treatments in rodents. Project 6 links EF to healthcare utilization and is supplemented with a qualitative investigation of EF-related barriers to treatment engagement for those with substance use concerns. Project 7 uses innovative whole-person modeling to integrate the multi-modal data generated across projects, applying clustering and deep learning methods to identify patient subtypes and drive future cross-disciplinary initiatives. DiscussionThe CDiA program has promise to bring scientific domains together to uncover the diverse ways in which EFs are linked to SUD severity and functional recovery. These findings, supported by emerging clinical, preclinical, health service, and whole-person modeling investigations, will facilitate future discoveries about cognitive dysfunction in addiction and could enhance the future clinical care of individuals seeking treatment for SUDs. Scope statementSubstance use disorders (SUDs) are a leading contributor to psychiatric morbidity, mortality, and functional impairment. Cognitive dysfunction contributes substantially to this impairment, and plays a prominent role in causal models of addiction. Executive dysfunction in particular is linked to the onset and persistence of SUDs. Large-scale, multidisciplinary efforts are necessary to elucidate the nature and course of cognitive deficits and associated functional outcomes in SUDs. The Cognitive Dysfunction in the Addictions (CDiA) integrative, translational research program undertakes to advance the study of cognitive dysfunction in SUDs, with a focus on impairments in executive function. The Program incorporates preclinical, clinical, and health systems level investigation. The proposed investigations are well positioned to determine how experimental findings translate from humans to animals (reverse translational approach), as well as how preclinical findings will translate into the development of novel treatment avenues.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.